Screener
Bioventus BVS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Comprehensive income attributable to noncontrolling interest | (2,984) | (2,118) | (3,728) | (1,555) |
| Comprehensive income attributable to Bioventus Inc. | $34,392 | $8,747 | $37,126 | $6,621 |
| Income per share of Class A common stock: | ||||
| Basic | $0.49 | $0.11 | $0.54 | $0.07 |
| Diluted | $0.47 | $0.11 | $0.52 | $0.07 |
| Weighted-average shares of Class A common stock outstanding: | ||||
| Basic | 67,869,148 | 66,500,433 | 67,589,178 | 66,258,679 |
| Diluted | 70,838,486 | 68,536,759 | 70,429,825 | 68,765,591 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's EPS (diluted)?
- Bioventus (BVS) reported EPS (diluted) of $0.47 in Q2 2026.
- How has Bioventus's EPS (diluted) changed year-over-year?
- Bioventus's EPS (diluted) increased by 327.3% year-over-year, from $0.11 to $0.47.
- What is the long-term trend for Bioventus's EPS (diluted)?
- Over 4 years (2021 to 2025), Bioventus's EPS (diluted) has grown at a 2.4% compound annual growth rate (CAGR), from -$0.30 to $0.33.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Bioventus's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude